CD169+CXCL12-CXCR4

Dongliang Wang1, Jie Ling1, RongQiang Tan2

  • 1State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China.

iScience
|March 5, 2024
PubMed
概括

格雷夫斯病患者可能会出现眼睛并发症. CD169+古典单细胞是格雷夫斯眼病 (GO) 进展和炎症的关键驱动因素,表明新的治疗点.